Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.

V DeGruttola; L A Beckett; R W Coombs; J M Arduino; H H Balfour; S Rasheed; F B Hollinger; M A Fischl; P Volberding

doi:10.1093/infdis/169.4.713

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.

Identifier:nobleid.org/w1/20260515/3161FCF4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3161FCF4.svg?ark=w1%2F20260515%2F3161FCF4)](https://nobleid.org/work/w1/20260515/3161FCF4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.

Identifier:nobleid.org/w1/20260515/3161FCF4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3161FCF4.svg?ark=w1%2F20260515%2F3161FCF4)](https://nobleid.org/work/w1/20260515/3161FCF4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work